Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases.
The ICER favored budesonide/formoterol over fluticasone/vilanterol in terms of cost-effectiveness. A 5.5% reduction in patient exacerbations indicated decreased disease burden. While not statistically significant, fewer exacerbations per patient might still cut costs by lowering emergency visits and hospitalizations.
Authors
- Herman Soto–Molina (ORCID: https://orcid.org/0000-0001-8479-4407)
- Jorge Salas‐Hernandez (ORCID: https://orcid.org/0000-0002-2050-5626)
- Erika del Carmen López‐Estrada (ORCID: https://orcid.org/0000-0003-4542-5224)
- Monserrat Evelia Arroyo-Rojas
- María del Carmen Cano-Salas (ORCID: https://orcid.org/0000-0003-3954-1368)
- Homero Garcés-Flores
- José L Miguel-Reyes (ORCID: https://orcid.org/0000-0002-4071-3254)
- Sergio Ricardo García-García
- Mauricio Castañeda-Valdivia
- Monserrat Escobar-Preciado
- Silvia Guzmán-Vázquez
Institutions
- Bank of Mexico (MX)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Centro Médico ABC (MX)
- Hospital Regional de Alta Especialidad del Bajío (MX)
Publication Details
- Journal
- Revista Alergia México
- Published
- 2024-12-27
- DOI
- https://doi.org/10.29262/ram.v71i4.1295
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca